Kadimastem Ltd
OTC: KMSTF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ronen Twito
- Employees
- 11
- Headquarters
- Ness Ziona, Israel
- IPO year
- 2021
- Market cap
- $9.5M
- Website
- https://www.kadimastem.com
Loading KMSTF…
Loading profile data…Frequently asked questions about KMSTF
What does Kadimastem Ltd (KMSTF) do?
Kadimastem Ltd, an Israeli biopharmaceutical company, focuses on pioneering regenerative medicine therapies that utilize cells originating from human embryonic stem cells, primarily targeting neurodegenerative disorders. Its developmental pipeline features AstroRx, a clinical-grade human astrocyte therapy presently undergoing Phase 1/2a clinical...
Where does KMSTF trade?
Kadimastem Ltd (KMSTF) trades on the Other OTC.
What sector is KMSTF in?
Kadimastem Ltd (KMSTF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kadimastem Ltd?
Ronen Twito is the chief executive officer of Kadimastem Ltd (KMSTF).
Where is Kadimastem Ltd headquartered?
Kadimastem Ltd is headquartered in Israel.
Does KMSTF pay a dividend?
Kadimastem Ltd (KMSTF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KMSTF go public?
Kadimastem Ltd (KMSTF) completed its initial public offering in 2021.